Principal/Senior Scientist
NewLimit
Principal/Senior Scientist
NewLimit
Develops epigenetic medicines to extend healthspan
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.
NewLimit is seeking a Senior/Principal Scientist with deep expertise in molecular biology and translational biomarker assay development. In this role, you will lead the discovery, development, and qualification of pharmacodynamic (PD) biomarker assays that characterize the biological activity of our mRNA-LNP medicines in preclinical and IND-enabling studies. You will serve as a technical leader within our bioanalytical function, shaping PD biomarker strategy from discovery through fit-for-purpose qualification to advance our therapeutic programs toward clinical milestones.
NewLimit provides generous benefits so our team can remain focused on our mission:
Salary Range: $155,000 to $200,000. Compensation for the role will depend on a number of factors, including a candidate’s qualifications, skills, competencies, and experience. NewLimit offers a competitive benefits package, which includes a 401k, healthcare coverage, and 20 days of PTO. Learn more at: https://www.newlimit.com/careers *This compensation and benefits information is based on Company's good faith estimate as of the date of publication and may be modified in the future.
NewLimit develops medicines that aim to extend healthy years by reprogramming the epigenome of aging cells. It works by identifying aging-related epigenetic changes using single-cell genomics, machine learning, and high-throughput functional assays, then creating interventions to reverse those changes in targeted tissues such as the immune system and liver. Compared with others, NewLimit combines a specific focus on epigenetic reprogramming with a data-driven, tissue-targeted pipeline and pursues partnerships with pharma and biotech players to develop its proprietary medicines. Its goal is to deliver a new class of medicines that significantly increases the healthspan for patients with age-related diseases.
Explore more opportunities at NewLimit